The open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of the locally administered product in a total of 22 patients with primary or recurrent non-muscle invasive bladder cancer, and is expected to be well tolerated.
Lasse Leino, CEO, BioCis Pharma, said: We are pleased to advance to clinical testing with the ProtoCure instillation solution.
“The ProtoCure cancer drug holds great promise for patients suffering from superficial bladder cancer. We are committed to take the product quickly to more extensive clinical efficacy testing after this preliminary safety study. We expect to get results from this study by the first quarter of 2010, he added.